A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Key Inclusion Criteria: * Adult patients, 18 years or older (16 years or older in the UK) * Diagnosed with Pachyonychia Congenita (PC), genetically confirmed Key Exclusion Criteria: * Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications. * Any significant concurrent condition (including conditions involving or inferior to the ankle) that could adversely affect the patient's participation and/or the assessment of the safety and efficacy in the study. * Participation in any other interventional clinical research trial within 30 days prior to the screening visit or during the patient's participation in this study